Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C37H48N6O5S2 |
Molecular Weight | 720.9478 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@@]([H])(C(=N[C@@]([H])(Cc1ccccc1)C[C@@]([H])([C@]([H])(Cc2ccccc2)N=C(O)OCc3cncs3)O)O)N=C(N(C)Cc4csc(C(C)C)n4)O
InChI
InChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
Molecular Formula | C37H48N6O5S2 |
Molecular Weight | 720.9478 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment:: description was created based on several sources, including:
http://www.rxlist.com/norvir-drug.htm
https://www.drugs.com/mtm/ritonavir.html
http://www.wikidoc.org/index.php/Ritonavir
Curator's Comment:: description was created based on several sources, including:
http://www.rxlist.com/norvir-drug.htm
https://www.drugs.com/mtm/ritonavir.html
http://www.wikidoc.org/index.php/Ritonavir
Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14634041 | https://www.ncbi.nlm.nih.gov/pubmed/9107549
Curator's Comment:: Known to be CNS penetrant in guinea pig and rats. Human data not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11159797 |
2.2 µM [IC50] | ||
Target ID: CHEMBL2364675 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10952482 |
0.14 µM [IC50] | ||
Target ID: CHEMBL243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17627597 |
0.01 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NORVIR Approved UseKALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology (12.4) and Clinical Studies (14) Launch Date8.2563839E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.2 μg/mL |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RITONAVIR unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
129 μg × h/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
RITONAVIR unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5 h |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RITONAVIR unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
RITONAVIR unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: |
healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: |
Disc. AE: Death fetal... AEs leading to discontinuation/dose reduction: Death fetal (1 patient) Sources: |
50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: |
healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: |
Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (grade 2, 1 patient) Sources: |
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
Other AEs: Gastrointestinal disorder NOS, Lipids abnormal... Other AEs: Gastrointestinal disorder NOS Sources: Lipids abnormal Insulin resistance Lipoatrophy |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Death fetal | 1 patient Disc. AE |
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: |
healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: |
Hypertension | grade 2, 1 patient Disc. AE |
50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: |
healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: |
Gastrointestinal disorder NOS | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
|
Insulin resistance | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
|
Lipids abnormal | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
|
Lipoatrophy | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: - |
yes [Km 0.05 uM] | |||
Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: - |
yes [Km 0.21 uM] | |||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors. | 1999 Sep 23 |
|
HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. | 1999 Sep-Oct |
|
Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. | 2000 Aug |
|
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. | 2000 Aug |
|
Potential interaction between ritonavir and carbamazepine. | 2000 Jul |
|
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. | 2000 Nov 10 |
|
Inhibition of HIV-1 protease by a boron-modified polypeptide. | 2000 Oct 1 |
|
Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. | 2000 Sep |
|
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. | 2000 Sep |
|
Saquinavir soft gelatin capsule: a comparative safety review. | 2001 |
|
Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. | 2001 Apr |
|
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. | 2001 Apr |
|
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. | 2001 Apr |
|
Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. | 2001 Apr 1 |
|
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. | 2001 Apr 13 |
|
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. | 2001 Apr 13 |
|
Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. | 2001 Apr 15 |
|
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. | 2001 Apr 15 |
|
[Overcoming weaknesses in therapy. Protease inhibitors with high IQ]. | 2001 Apr 2 |
|
[Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis]. | 2001 Apr 2 |
|
[No resistance even after 1 year. New drug combination against HIV]. | 2001 Apr 2 |
|
[Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV]. | 2001 Apr 21 |
|
Antiviral drugs: current state of the art. | 2001 Aug |
|
Use of HIV protease inhibitors as pharmacoenhancers. | 2001 Feb |
|
[Long-term immunologic response in HIV-infected patients with CD4 cell counts = 50/mm3 when initiating protease inhibitor therapy]. | 2001 Feb |
|
Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study. | 2001 Feb |
|
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. | 2001 Feb |
|
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. | 2001 Feb |
|
Genetic analysis of hiv type 1 strains in bujumbura (burundi): predominance of subtype c variant. | 2001 Feb 10 |
|
Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. | 2001 Jan 1 |
|
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. | 2001 Jan 20 |
|
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. | 2001 Jan 5 |
|
New developments in anti-HIV chemotherapy. | 2001 Jan-Feb |
|
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART. | 2001 Jul |
|
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. | 2001 Jun |
|
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. | 2001 Jun 1 |
|
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. | 2001 Jun 1 |
|
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. | 2001 Jun 1 |
|
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. | 2001 Jun 15 |
|
Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. | 2001 Jun 15 |
|
A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. | 2001 Mar |
|
The safety and antiviral effect of protease inhibitors in children. | 2001 Mar |
|
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. | 2001 Mar 1 |
|
Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors. | 2001 Mar 26 |
|
[HIV: a guide on management of seropositive patients]. | 2001 Mar 3 |
|
ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis. | 2001 Mar 30 |
|
Lopinavir/ritonavir. | 2001 Mar-Apr |
|
P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays. | 2001 May |
|
A potential role for interleukin-7 in T-cell homeostasis. | 2001 May 15 |
|
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography. | 2001 May 5 |
Patents
Sample Use Guides
600 mg twice-day with meals.
Ritonavir should be started at no less than 300 mg twice daily and increased at 2 to 3 day intervals by 100 mg twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12964850
Ritonavir diminished the growth rate of Candida albicans as well as the activity of its secreted aspartyl proteinases (Saps) in a nitrogen-limited medium, yeast carbon base and bovine serum albumin (YCB-BSA). This inhibition occurred in a dose-dependent fashion; with 8 mg/l of ritonavir a partial growth inhibition (44%) was produced.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:55:55 UTC 2021
by
admin
on
Fri Jun 25 20:55:55 UTC 2021
|
Record UNII |
O3J8G9O825
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
853
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-ATC |
J05AR10
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-ATC |
J05AE03
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-VATC |
QJ05AE03
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
FDA ORPHAN DRUG |
549816
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-VATC |
QJ05AR10
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-ATC |
J05AP52
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
LOPINAVIR (AUHTORIZED: HIV INFECTIONS)
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-ATC |
J05AX66
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
NCI_THESAURUS |
C97366
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
KALETRA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LPV/R)
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-ATC |
J05AR23
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-ATC |
J05AP53
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
NDF-RT |
N0000191001
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
FDA ORPHAN DRUG |
509215
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
NDF-RT |
N0000175889
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
FDA ORPHAN DRUG |
484715
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
NDF-RT |
N0000000246
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
VIEKIRAX (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
WHO-ATC |
J05AX67
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
NORVIR (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RITONAVIR
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Description: A white or almost white powder. Solubility: Practically insoluble in water, freely soluble in methanol R, sparingly soluble in acetone R and very slightly soluble in acetonitrile R. Category: Antiretroviral (Protease Inhibitor). Storage: Ritonavir should be kept in a well-closed container, protected from light. Additional information: Ritonavir may exhibit polymorphism. Requirements: Ritonavir contains not less than 98.5 % and not more than 101.0 % of C37H48N6O5S2, calculated with reference to the dried substance. | ||
|
O3J8G9O825
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
CHEMBL163
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
7449
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
SUB10342MIG
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
RITONAVIR
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
85762
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | RxNorm | ||
|
N0000182137
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Cytochrome P450 2D6 Inhibitors [MoA] | ||
|
N0000182141
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Cytochrome P450 3A4 Inhibitors [MoA] | ||
|
N0000187064
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Cytochrome P450 2B6 Inducers [MoA] | ||
|
DB00503
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
D019438
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
Ritonavir
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
N0000185607
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Cytochrome P450 2C19 Inducers [MoA] | ||
|
2391
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
N0000191266
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Cytochrome P450 1A2 Inducers [MoA] | ||
|
N0000190113
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Breast Cancer Resistance Protein Inhibitors [MoA] | ||
|
N0000185507
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Cytochrome P450 2C9 Inducers [MoA] | ||
|
155213-67-5
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
N0000190117
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | UDP Glucuronosyltransferases Inducers [MoA] | ||
|
N0000190118
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Cytochrome P450 3A Inducers [MoA] | ||
|
1604814
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | USP-RS | ||
|
M9636
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Merck Index | ||
|
1604803
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | USP-RS | ||
|
N0000190114
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | Cytochrome P450 3A Inhibitors [MoA] | ||
|
392622
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
7160
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
8804
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
C1609
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
155213-67-5
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | |||
|
N0000185503
Created by
admin on Fri Jun 25 20:55:55 UTC 2021 , Edited by admin on Fri Jun 25 20:55:55 UTC 2021
|
PRIMARY | P-Glycoprotein Inhibitors [MoA] |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> INHIBITOR |
POTENT
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INDUCER | |||
|
TRANSPORTER -> INDUCER | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
METABOLIC ENZYME -> INHIBITOR |
POTENT
|
||
|
METABOLIC ENZYME -> INHIBITOR |
POTENT
|
||
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
FECAL
|
||
|
METABOLITE ACTIVE -> PARENT |
37.3% in feces
30.4% in urine
MAJOR
FECAL; URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
FECAL
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
Mixture of BOC-aminoalcohol and isobutoxycarbonyl aminoalcohol- 0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
Mixture of ureidovaline and N-deacylvaline ritonavir-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
Mixture of BOC-aminoalcohol and isobutoxycarbonyl aminoalcohol-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
Mixture of ureidovaline and N-deacylvaline ritonavir-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||